AlphaLISA and HT-SPR together can help you better understand FcRn biology

Mammalian cell line generation is a rate-limiting step in early CMC development and there is a constant desire to increase throughput. The implementation of automation is one way to increase throughput. This webinar will address some factors to consider during the process of automating a manual workflow including details of culture vessel changes, liquid handling adaptation, and changes of the cell line developer’s job during the process. With an end result of increased throughput, automation potentially allows cell line development to begin prior to final molecule selection. This can remove cell line development off the critical path of CMC development.

Successful development of advanced biotherapeutics relies on extensive characterization and tight quality control of protein interactions. Characterizing the binding properties of complex biomolecules, such as bispecific antibodies or reengineered probiotics, is a critical step.

As scientific innovation has led to new trial designs, modern cloud technologies have enabled the industry to better manage how clinical trials are executed. Newer, more advanced cloud applications now offer unified data and process models, allowing organizations to manage their end-to-end clinical trial process within a single system. Rather than juggling individual point solutions, innovative organizations are using a unified clinical platform for greater efficiency, quality, and speed of execution. Join Veeva and Idorsia to learn how your organization can leverage a unified clinical operating model and drive new levels of efficiency across the entire clinical ecosystem.

This webinar will demonstrate how the power of a single-cell multiomic approach can be harnessed to comprehensively characterize T cells, and precisely monitor changes in differentiation, activation, and exhaustion signatures during in vitro cell stimulation.